Program

SUNDAY, NOVEMBER 7

Educational Sessions 1-2

10:00 a.m.-11:30 a.m.

• Metabolomics: An Emerging Tool for Defining Complex Biological Systems in Health and Disease

  Chairperson: Steven S. Gross, Weill Cornell Medical College, New York, NY

  Untargeted plasma metabolite profiling: Strategies and approaches for comprehensive characterization of gene mutations and drug actions
  Steven S. Gross

  Metabolomics of disease progression
  Christopher Beecher, University of Michigan, Ann Arbor, MI

  Metabolomics as a unique biochemical approach for therapeutic discovery
  Gary Siuzdak, The Scripps Research Institute, La Jolla, CA

• Trends in Molecular Epidemiology Research

  Chairperson: Gloria M. Petersen, Mayo Clinic Cancer Center, Rochester, MN

  Introduction
  Gloria M. Petersen

  Gene, environment, and risk factor interaction in pancreatic cancer
  Harvey A. Risch, Yale University, New Haven, CT

  Genomic technologies for variant detection and measurement
  John D. Carpten, Translational Genomics Research Institute, Phoenix, AZ

  Molecular genetic research: Translating discovery into risk assessment and genetic testing
  Gloria M. Petersen

Professional Advancement Session

Chairperson: Margaret R. Spitz, University of Texas MD Anderson Cancer Center, Houston, TX
11:30 a.m.-1:00 p.m.

Opening Remarks
Margaret R. Spitz; and Elizabeth H. Blackburn, University of California, San Francisco, CA

Panel Discussion

• How do I get promoted? (Download presentation *)
  Judy E. Garber, Dana-Farber Cancer Institute, Boston, MA
• How do I get my papers published? (Download presentation *)
  William G. Nelson, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
• How do I get my grants funded under the new guidelines? (Download presentation *)
  Electra D. Paskett, Ohio State University Comprehensive Cancer Center, Columbus, OH

* - Adobe Acrobat Reader required

• Discussants
  Powel H. Brown, University of Texas MD Anderson Cancer Center, Houston, TX
  Andrew J. Dannenberg, Cornell University Weill Medical College, New York, NY
  Judy E. Garber
  Stephen B. Gruber, University of Michigan, Ann Arbor, MI
  Samir M. Hanash, Fred Hutchinson Cancer Research Center, Seattle, WA
  William G. Nelson
  Electra D. Paskett
  Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, MN
  Elizabeth A. Platz, Johns Hopkins University School of Public Health, Baltimore, MD
  Brian J. Reid, Fred Hutchinson Cancer Research Center, Seattle, WA
  Harvey A. Risch, Yale University, New Haven, CT
  Margaret R. Spitz
  Eva Szabo, National Cancer Institute, Bethesda, MD

Lunch on own

11:30 a.m.-1:00 p.m.

Educational Session 3-4

1:00 p.m.-2:30 p.m.

• Epigenetics

  Chairperson: Ari M. Melnick, Weill Cornell Medical College, New York, NY

  Epigenetic progression in cancer: Implications for prevention
  James G. Herman, Johns Hopkins University, Baltimore, MD
  
  The clinical and biological impact of aberrant DNA methylation patterning in human cancer 
  Ari M. Melnick

  Therapeutic targeting of oncogenic epigenetic modifiers
  Kapil N. Bhalla, The University of Kansas Cancer Center, Kansas City, KS

• Team Science and Transdisciplinary Approaches to Cancer Prevention Research Within and Across Institutions

  Chairperson: Sarah Gehlert, Washington University, St. Louis, MO

  Fostering team science and transdisciplinary approaches to cancer prevention: The Centers for Population Health and Health Disparities experience
  Sarah Gehlert

  Team science and transdisciplinarity in cancer prevention research across the life cycle: The Breast Cancer and the Environment Research Program experience
  Robert A. Hiatt, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  The NCI perspective on the significance and importance of team science and transdisciplinarity for cancer prevention research: The TTURC experience
  Glen Morgan, National Cancer Institute, Bethesda, MD

Educational Sessions 5-6

2:45 p.m.-4:15 p.m.

• Clinical Trial Novel Design: Retooling Drugs for Prevention

  Chairperson: Andrea U. DeCensi, E.O. Ospedali Galliera, Genova, Italy

  Common drugs associated with reduced cancer risk
  Gad Rennert, CHS National Cancer Control Center, Haifa, Israel

  Efficient trial designs and suitable cohorts to assess preventive agents
  Jack Cuzick, Cancer Research UK, Queen Mary University of London, London, United Kingdom

  Presurgical models to effectively screen preventive agents
  Andrea U. DeCensi

• The Indigenous Gut Microbiota in Colon Cancer

  Chairperson: Vincent B. Young, University of Michigan, Ann Arbor, MI

  Understanding the structure and function of the gut microbiota
  Vincent B. Young

  Colonic bacteria, inflammation, and colon cancer
  Cynthia L. Sears, Johns Hopkins University, Baltimore, MD

  The microbiota and development of colitis-associated colorectal cancer
  Christian Jobin, University of North Carolina, Chapel Hill, NC

Special Session: View From the NCI

4:30 p.m.-5:15 p.m.

View from the NCI: NCI's Division of Cancer Prevention
Peter Greenwald, National Cancer Institute, Division of Cancer Prevention, Bethesda, MD

View from the NCI: Division of Cancer Control and Population Sciences
Robert T. Croyle, National Cancer Institute, Division of Cancer Control and Population Sciences, Bethesda, MD

Opening Plenary Session

6:00 p.m.-7:30 p.m.

Welcome and Remarks
Margaret Foti, CEO, American Association for Cancer Research, Philadelphia, PA

Eva Szabo, Scientific Program Committee Chairperson, National Cancer Institute, Bethesda, MD

Keynote Address
Telomere biology and cancer
Elizabeth H. Blackburn, University of California, San Francisco, CA

Distinguished Lecture on Targets for Cancer Prevention
Inflammation and cancer: Interweaving microRNA, innate immune, and p53 pathways
Curtis C. Harris, National Cancer Institute, Bethesda, MD

View recent articles from these speakers in AACR journals.

Opening Reception

7:30 p.m.-9:00 p.m.

MONDAY, NOVEMBER 8

Plenary Session 1: Personalized Prevention

Chairperson: Scott M. Lippman, University of Texas MD Anderson Cancer Center, Houston, TX
8:00 a.m.-10:00 a.m.

Proximity of personalized risk and predictive markers to the clinic
Scott M. Lippman

Nicotine-dependence pharmacogenetics: Implications for personalized therapy
Robert A. Schnoll, University of Pennsylvania, Philadelphia, PA

ODC genotype as prognostic and predictive factors in colorectal carcinogenesis and prevention
Eugene W. Gerner, University of Arizona, Tucson, AZ

Selenium, genes, and cancer prevention
Jing Ma, Brigham and Women’s Hospital, Boston, MA

View recent articles from these speakers in AACR journals.

Concurrent Sessions 1-3

10:15 a.m.-12:00 p.m.

• Infections

  Chairperson: Douglas R. Lowy, National Cancer Institute, Bethesda, MD

  Current and future HPV vaccines
  Douglas R. Lowy

  Immunotherapy of established lesions caused by high-risk HPV
  Cornelis J.M. Melief, University Hospital Leiden, Leiden, The Netherlands

  HBV vaccination to prevent hepatocellular carcinoma
  Mei-Hwei Chang, National Taiwan University Hospital, Taipei, Taiwan

• Recently Completed Developmental Trials in Chemoprevention

  Chairperson: Howard H. Bailey, University of Wisconsin Comprehensive Cancer Center, Madison, WI

  Pertinent chemoprevention drug development issues in today's session
  Howard H. Bailey

  Phase 0 chemoprevention trial of SR13668, a novel AKT inhibitor, in normal volunteers
  Joel M. Reid, Mayo Clinic College of Medicine, Rochester, MI

  Phase II study of genistein in men with prostate cancer
  Raymond C. Bergan, Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, IL

  Phase IIB randomized clinical chemoprevention trial of a soybean-derived compound (Bowman-Birk inhibitor concentrate) for oral leukoplakia
  Frank L. Meyskens, University of California Irvine Chao Family Comprehensive Cancer Center, Orange, CA

  Phase IIB study to evaluate the safety and efficacy of topical difluoromethylornithine and topical diclofenac in the treatment of sun-damaged skin
  Joanne M. Jeter, Arizona Cancer Center, Tucson, AZ

  Discussion
  Moderator: Howard H. Bailey

  In Memoriam: Karen Aubrey Johnson (1946-2010)
  A tribute to Dr. Karen Johnson will take place from 12:00-12:20.

• Interventions to Reduce Cancer Health Disparities

  Chairperson: Electra D. Paskett, Ohio State University Comprehensive Cancer Center, Columbus, OH

  Community-based intervention to reduce liver cancer disparities in Asian Americans: A cluster randomized trial
  Roshan Bastani, UCLA School of Public Health and Jonsson Comprehensive Cancer Center, Los Angeles, CA

  Randomized trial of a lay health advisor and computer intervention to increase mammography screening in African American women
  Electra D. Paskett

  Improving follow-up to abnormal breast cancer screening in an urban population: A patient navigation intervention
  Tracy A. Battaglia, Boston University School of Medicine, Boston, MA

  Inequalities in colorectal cancer screening uptake: Results from the first 2.6 million invitations in the organized screening program in the UK*
  Jane Wardle, University College London, London, United Kingdom

Lunch on own

12:00 p.m.-1:15 p.m.

Concurrent Sessions 4-6

1:15 p.m.-3:00 p.m.

• Molecular Targets for Cancer Prevention

  Chairperson: Eva Szabo, National Cancer Institute, Bethesda, MD

  PPARgamma in aerodigestive cancer prevention
  Eva Szabo

  Strategies to target the insulin/IGF-I receptor family for cancer prevention
  Michael N. Pollak, McGill University, Montreal, QC, Canada

  PI3K as a target for lung cancer chemoprevention
  Andrea H. Bild, University of Utah, Salt Lake City, UT

  STAT2 contributes to promotion of colorectal and skin carcinogenesis*
  Ana M. Gamero, Temple University, Philadelphia, PA

• Prostate Cancer

  Chairperson: Raymond C. Bergan, Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, IL

  Early molecular changes in prostate carcinogenesis
  William G. Nelson, Johns Hopkins University, Baltimore, MD

  The role of estrogen in prostate cancer development and prevention
  Shuk-Mei Ho, University of Cincinnati, Cincinnati, OH

  Decision making in prostate cancer screening
  Kathryn L. Taylor, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

  Randomized presurgical trial of finasteride vs. flutamide vs. placebo in prostate cancer*
  Silvia Zanardi, E.O. Ospedali Galliera, Genoa, Italy, and European Institute of Oncology, Milan, Italy

• Individualized Diet and Cancer Prevention

  Chairperson: Johanna Wyss Lampe, Fred Hutchinson Cancer Research Center, Seattle, WA

  Soy foods and cancer risk: How does the relation vary in individuals with different ethnicity, diet, and lifestyle?
  Gertraud Maskarinec, Cancer Research Center of Hawaii, Honolulu, HI

  Green tea and pomegranate: The role of metabolites in chemoprevention
  Susanne M. Henning, David Geffen School of Medicine, University of California, Los Angeles, CA

  Vegetable constituents and biotransformation enzymes: The effect of genetic variation on response
  Johanna Wyss Lampe

  Interactions between plasma levels of 25-hydroxyvitamin D and insulin-like growth factor (IGF)-1, IGF-binding proteins, and C-peptide with risk of colorectal cancer*
  Kana Wu, Harvard School of Public Health, Boston, MA

Plenary Session 2: New Approaches to Identifying High-Risk Populations

Chairperson: Avrum E. Spira, Boston University, Boston, MA
3:15 p.m.-5:15 p.m.

Identifying the smoker at risk for lung cancer
Avrum E. Spira

Cancer risk-stratification through biophotonic detection of field carcinogenesis
Hemant K. Roy, University of Chicago Pritzker School of Medicine, Evanston, IL

Somatic evolution and neoplastic progression in Barrett’s esophagus: Lessons in space and time
Brian J. Reid, Fred Hutchinson Cancer Research Center, Seattle, WA

New insights into genetic susceptibility to breast cancer
Douglas Easton, University of Cambridge, Cambridge, United Kingdom

View recent articles from these speakers in AACR journals.

Ninth Annual AACR-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research Lecture

5:15 p.m.-6:15 p.m.

Validating biomarkers to probe the etiology and prevention of hepatocellular carcinoma
John D. Groopman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

Behavioral Science in Cancer Research Networking Event

6:00 p.m.-7:30 p.m.

Please visit the Networking Sessions and Social Events webpage for details.

Poster Session A

6:15 p.m.-8:45 p.m.

TUESDAY, NOVEMBER 9

Report on AACR-NCI Think Tank: Charting the Future of Cancer Prevention

Chairperson: Raymond N. DuBois, University of Texas MD Anderson Cancer Center, Houston, TX
7:00 a.m.-8:00 a.m.

Plenary Session 3: Bioenergetics and Cancer

Co-Chairpersons: John A. Milner, National Cancer Institute, Rockville, MD, and Sharon Ross, National Cancer Institute, Rockville, MD
8:00 a.m.-10:00 a.m.

Introduction
John A. Milner

Exercise, adiposity, and cancer
Anne McTiernan, Fred Hutchinson Cancer Research Center, Seattle, WA

Nrf2 and cancer protection
Rafael de Cabo, NIH-NIA Laboratory of Experimental Gerontology, Baltimore, MD

Cancer cure and prevention: Lessons learned from a small but highly effective agent
Peter L. Pedersen, Johns Hopkins University, Baltimore, MD

Obesity and mTORC1 signaling pathway
George Thomas, University of Cincinnati, Cincinnati, OH

View recent articles from these speakers in AACR journals.

Concurrent Sessions 7-9

10:15 a.m.-12:00 p.m.

• Lung Cancer Prevention

  Chairperson: Jenny T. Mao, University of New Mexico, Albuquerque, NM

  Polycyclic aromatic hydrocarbon tetraols: Potentional phenotypic indicators of lung cancer susceptibility in smokers
  Stephen S. Hecht, Masonic Cancer Center, University of Minnesota, Minneapolis, MN

  Natural history of bronchial preneoplasia
  Stephen Lam, British Columbia Cancer Agency, Vancouver, BC, Canada

  Neutrophil elastase as a chemopreventive target for lung cancer
  McGarry Houghton, University of Pittsburgh, Pittsburgh, PA

  Efficient designs for lung cancer prevention trials: Lessons learned and moving forward
  J. Jack Lee, University of Texas MD Anderson Cancer Center, Houston, TX

• Karen A. Johnson Memorial Session:
  Novel Targets and Strategies for Breast Cancer Prevention

  Chairperson: Powel H. Brown, University of Texas MD Anderson Cancer Center, Houston, TX

  Implications of the cancer stem cell hypothesis for breast cancer prevention
  Max S. Wicha, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  Breast cancer prevention: Predictors and outcomes of patient decision making
  Suzanne C. O'Neill, Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC

  PARP inhibitors: Early promise in breast and ovarian cancer prevention
  Judy E. Garber, Dana-Farber Cancer Institute, Boston, MA

  Effects of presurgical administration of tea polyphenols in women with operable breast cancer*
  Julie L. Campbell, Columbia University Medical Center, New York, NY

  Please note that the tribute to Dr. Karen Johnson has been moved to Monday, November 8 from 12:00 p.m. to 12:20 p.m. in Room 201B.

• Molecular Approaches to Early Detection

  Chairperson: Samir M. Hanash, Fred Hutchinson Cancer Research Center, Seattle, WA

  Autoantibodies and early detection of lung cancer
  Samir M. Hanash

  The EGFR conundrum: EGFR-based diagnostics in the era of precision medicine
  Nita J. Maihle, Yale University School of Medicine, New Haven, CT

  Molecular approaches to early detection of pancreatic cancer
  Michael A. Hollingsworth, University of Nebraska Medical Center Eppley Cancer Center, Omaha, NE

  Identification of age-dependent biomarkers for early detection of breast cancer using metabolite profiling: A multisite study*
  Vincent M. Asiago, Purdue University, West Lafayette, IN

Lunch on own

12:00 p.m.-1:15 p.m.

Concurrent Sessions 10-12

1:15 p.m.-3:00 p.m.

• The Microenvironment

  Chairperson: Thea D. Tlsty, University of California, San Francisco, CA

  Stromal-epithelial interactions in early carcinogenesis
  Thea D. Tlsty

  Stromal signals from the involuting microenvironment that are important in postpartum breast cancer
  Pepper Jo Schedin, University of Colorado Denver, Aurora, CO

  Profiling of tumors to identify factors that contribute to cancer health disparities
  Stephan Ambs, National Cancer Institute, Bethesda, MD

  A new resource to accelerate research into the cause and prevention of breast cancer: The Love/Avon Army of Women*
  Leah Wilcox, Dr. Susan Love Research Foundation, Santa Monica, CA

• Advances in the Genetics, Screening and Prevention of Cancers in Cancer Susceptibility Syndromes

  Chairperson: Katherine L. Nathanson, University of Pennsylvania, Philadelphia, PA

  Genetics of pheochromocytoma and paraganglioma defines medical management
  Katherine L. Nathanson

  Whole-body MRI and PET for screening in patients with neurofibromatosis
  Scott R. Plotkin, Massachusetts General Hospital, Boston, MA

  Cancer prevention in Lynch syndrome
  Sir John Burn, Institute of Human Genetics, International Center for Life, Newcastle-upon-Tyne, United Kingdom

  The willingness to accept chemoprevention strategies by women at increased risk of breast cancer*
  Mfon Cyrus-David, University of Texas Health Science Center, Houston, TX

• Inflammation and Cancer Prevention

  Chairperson: Andrew J. Dannenberg, Weill Cornell Medical College, New York, NY

  The prostaglandin-aromatase connection: Implications for breast carcinogenesis
  Andrew J. Dannenberg

  The inflammation-EMT-cancer initiating cell axis in the pathogenesis of lung cancer: Breaking ground in the pursuit of targeted chemoprevention
  Steven M. Dubinett, University of California, David Geffen School of Medicine, Los Angeles, CA

  The role of inflammation and stromal cells in gastrointestinal cancers
  Timothy C. Wang, Columbia University, New York, NY

  Low-fat diet reduces NF-κB regulated inflammatory cytokines and angiogenic factors in plasma of men with prostate cancer*
  Wendy Demark-Wahnefried, University of Alabama, Birmingham, AL

Plenary Session 4: Understanding Neoplastic Progression: Questions and Controversies

Chairperson: Carlo C. Maley, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
3:15 p.m.-5:15 p.m.

Evolutionary concepts of cancer
Carlo C. Maley

Cancer stem cells?
Simon Tavaré, University of Cambridge, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

Altered gene expression patterns in phenotypically normal cells from individuals heterozygous for mutations in tumor suppressor genes: Identification of candidate biomarkers of cancer risk
Alfonso Bellacosa, Fox Chase Cancer Center, Philadelphia, PA

Why do benign growths so often progress to malignant cancers?
John W. Pepper, University of Arizona, Tucson, AZ

View recent articles from these speakers in AACR journals.

Poster Session B

5:15 p.m.-7:45 p.m.

Molecular Epidemiology Working Group (MEG) Town Meeting and Reception

7:30 p.m.-9:00 p.m.

Please visit the Networking Sessions and Social Events webpage for details.

WEDNESDAY, NOVEMBER 10

Plenary Session 5: Bringing Prevention and Early Detection to the Public: A Global Perspective

Chairperson: Michael J. Thun, American Cancer Society, Atlanta, GA
8:00 a.m.-10:00 a.m.

Global trends in cancer: The imperative for prevention
Michael J. Thun

Policy and environmental approaches to cancer prevention: The New York City experience
Thomas A. Farley, New York City Department of Health and Mental Hygiene, New York, NY

From basic science to public health: The Canadian approach to oral leukoplakia
Miriam P. Rosin, British Columbia Cancer Research Center, Vancouver, BC, Canada

The Australian skin cancer prevention experience: Lessons learned and global challenges ahead
Craig Sinclair, Cancer Council Victoria, Carlton, VIC, Australia

View recent articles from these speakers in AACR journals.

Concurrent Sessions 13-15

10:15 a.m.-12:00 p.m.

• Molecularly Based Approaches to Colorectal Cancer Prevention

  Chairperson: Paul J. Limburg, Mayo Clinic College of Medicine, Rochester, MN

  Immunotherapy for prevention of colorectal cancer
  Robert E. Schoen, University of Pittsburgh, Pittsburgh, PA

  Next-generation stool DNA testing
  David A. Ahlquist, Mayo Clinic College of Medicine, Rochester, MN

  HDAC inhibitors in colorectal cancer chemoprevention
  Roderick H. Dashwood, Linus Pauling Institute, Oregon State University, Corvallis, OR

  A novel approach for colorectal cancer chemoprevention by targeting APC-deficient cells for apoptosis
  Xiangwei Wu, University of Texas MD Anderson Cancer Center, Houston, TX

  Panel Discussion

• Head and Neck Cancer Prevention

  Chairperson: Mary E. Reid, Roswell Park Cancer Institute, Buffalo, NY

  Motivating individual behavior change through theory-driven community engagement
  Henrietta L. Logan, University of Florida, Gainesville, FL

  Implications of fluorescent screening for detection of premalignancy and cancer
  Mary E. Reid

  Identifying the premalignant lesion at high risk for progression to cancer
  Li Mao, University of Maryland Dental School, Baltimore, MD

  Randomized placebo controlled trial of pioglitazone for oral premalignant lesions: A cross consortium collaborative study in progress*
  Jay O. Boyle, Memorial Sloan-Kettering Cancer Center, New York, NY

• Communicating Cancer Risks: High-Risk Populations, the Public, and Physician Communication

  Chairperson: Mary B. Daly, Fox Chase Cancer Center, Philadelphia, PA

  Communicating cancer risk to high-risk patients and their families
  Mary B. Daly

  The importance of form, content, and context in the design and effectiveness of risk communication methods
  James G. Dolan, University of Rochester, Rochester, NY

  Making data talk: Communicating science to lay audiences
  Bradford W. Hesse, National Cancer Institute, Bethesda, MD

  HPV vaccine adherence in urban youth*
  J. Kathleen Tracy, University of Maryland School of Medicine, Baltimore, MD

Departure